nodes	percent_of_prediction	percent_of_DWPC	metapath
Losartan—SLC2A9—nephrolithiasis	0.362	0.54	CbGaD
Losartan—SLC22A12—nephrolithiasis	0.308	0.46	CbGaD
Losartan—SLC22A6—Hydrochlorothiazide—nephrolithiasis	0.0679	1	CbGbCtD
Losartan—Persistent dry cough—Hydrochlorothiazide—nephrolithiasis	0.0124	0.0887	CcSEcCtD
Losartan—SLC22A12—nephron—nephrolithiasis	0.0102	0.159	CbGeAlD
Losartan—Coxalgia—Hydrochlorothiazide—nephrolithiasis	0.0071	0.0509	CcSEcCtD
Losartan—SLC2A9—nephron—nephrolithiasis	0.00698	0.109	CbGeAlD
Losartan—Knee pain—Hydrochlorothiazide—nephrolithiasis	0.00628	0.045	CcSEcCtD
Losartan—Sinus disorder—Hydrochlorothiazide—nephrolithiasis	0.00628	0.045	CcSEcCtD
Losartan—ACE—renal artery—nephrolithiasis	0.00565	0.0883	CbGeAlD
Losartan—Panic disorder—Hydrochlorothiazide—nephrolithiasis	0.00513	0.0368	CcSEcCtD
Losartan—Fibromyalgia—Hydrochlorothiazide—nephrolithiasis	0.00472	0.0338	CcSEcCtD
Losartan—Anxiety disorder—Hydrochlorothiazide—nephrolithiasis	0.00383	0.0274	CcSEcCtD
Losartan—Dry cough—Hydrochlorothiazide—nephrolithiasis	0.00383	0.0274	CcSEcCtD
Losartan—Airway obstruction NOS—Hydrochlorothiazide—nephrolithiasis	0.00361	0.0259	CcSEcCtD
Losartan—Pain in arm—Hydrochlorothiazide—nephrolithiasis	0.00361	0.0259	CcSEcCtD
Losartan—Angiitis necrotising—Hydrochlorothiazide—nephrolithiasis	0.00324	0.0232	CcSEcCtD
Losartan—Xanthopsia—Hydrochlorothiazide—nephrolithiasis	0.00324	0.0232	CcSEcCtD
Losartan—Vasculitis necrotising—Hydrochlorothiazide—nephrolithiasis	0.00282	0.0203	CcSEcCtD
Losartan—AGTR1—nephron—nephrolithiasis	0.00267	0.0418	CbGeAlD
Losartan—Henoch-Schonlein purpura—Hydrochlorothiazide—nephrolithiasis	0.00261	0.0187	CcSEcCtD
Losartan—Obstructive airways disorder—Hydrochlorothiazide—nephrolithiasis	0.00261	0.0187	CcSEcCtD
Losartan—UGT1A1—urine—nephrolithiasis	0.00246	0.0384	CbGeAlD
Losartan—Sialoadenitis—Hydrochlorothiazide—nephrolithiasis	0.00242	0.0174	CcSEcCtD
Losartan—Cutaneous vasculitis—Hydrochlorothiazide—nephrolithiasis	0.00227	0.0163	CcSEcCtD
Losartan—Shoulder pain—Hydrochlorothiazide—nephrolithiasis	0.0022	0.0158	CcSEcCtD
Losartan—SLC22A12—nephron tubule—nephrolithiasis	0.00219	0.0343	CbGeAlD
Losartan—Atrioventricular block second degree—Hydrochlorothiazide—nephrolithiasis	0.00207	0.0148	CcSEcCtD
Losartan—SLC22A12—renal system—nephrolithiasis	0.00199	0.0312	CbGeAlD
Losartan—ACE—nephron—nephrolithiasis	0.00197	0.0309	CbGeAlD
Losartan—SLC22A12—kidney—nephrolithiasis	0.00193	0.0301	CbGeAlD
Losartan—SLC22A12—cortex of kidney—nephrolithiasis	0.00188	0.0294	CbGeAlD
Losartan—UGT1A10—renal system—nephrolithiasis	0.00175	0.0273	CbGeAlD
Losartan—UGT1A10—kidney—nephrolithiasis	0.00169	0.0264	CbGeAlD
Losartan—ACE—urine—nephrolithiasis	0.00158	0.0248	CbGeAlD
Losartan—Stiffness—Hydrochlorothiazide—nephrolithiasis	0.00156	0.0112	CcSEcCtD
Losartan—Gastric irritation—Hydrochlorothiazide—nephrolithiasis	0.00153	0.0109	CcSEcCtD
Losartan—SLC2A9—nephron tubule—nephrolithiasis	0.00151	0.0236	CbGeAlD
Losartan—SLC2A9—renal system—nephrolithiasis	0.00137	0.0214	CbGeAlD
Losartan—CYP2C19—urine—nephrolithiasis	0.00133	0.0208	CbGeAlD
Losartan—SLC2A9—kidney—nephrolithiasis	0.00132	0.0207	CbGeAlD
Losartan—SLC2A9—cortex of kidney—nephrolithiasis	0.00129	0.0202	CbGeAlD
Losartan—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.00128	0.00919	CcSEcCtD
Losartan—Trauma—Hydrochlorothiazide—nephrolithiasis	0.00124	0.00891	CcSEcCtD
Losartan—Sinus bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00121	0.00865	CcSEcCtD
Losartan—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.00121	0.00865	CcSEcCtD
Losartan—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.00113	0.00807	CcSEcCtD
Losartan—CYP1A2—urine—nephrolithiasis	0.00109	0.017	CbGeAlD
Losartan—CYP2C9—urine—nephrolithiasis	0.00103	0.0162	CbGeAlD
Losartan—Toothache—Hydrochlorothiazide—nephrolithiasis	0.000973	0.00698	CcSEcCtD
Losartan—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.000962	0.0069	CcSEcCtD
Losartan—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.000932	0.00668	CcSEcCtD
Losartan—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.000877	0.00629	CcSEcCtD
Losartan—CYP3A4—urine—nephrolithiasis	0.000788	0.0123	CbGeAlD
Losartan—SLC2A9—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000779	0.0133	CbGpPWpGaD
Losartan—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.000773	0.00554	CcSEcCtD
Losartan—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.000773	0.00554	CcSEcCtD
Losartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—AMBP—nephrolithiasis	0.000763	0.0131	CbGpPWpGaD
Losartan—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.000754	0.00541	CcSEcCtD
Losartan—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.00073	0.00524	CcSEcCtD
Losartan—Stinging—Hydrochlorothiazide—nephrolithiasis	0.00073	0.00524	CcSEcCtD
Losartan—SLC2A9—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000724	0.0124	CbGpPWpGaD
Losartan—SLC22A6—nephron tubule—nephrolithiasis	0.000714	0.0112	CbGeAlD
Losartan—SLC22A12—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000712	0.0122	CbGpPWpGaD
Losartan—UGT2B7—renal system—nephrolithiasis	0.000707	0.0111	CbGeAlD
Losartan—UGT2B7—kidney—nephrolithiasis	0.000684	0.0107	CbGeAlD
Losartan—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.000674	0.00483	CcSEcCtD
Losartan—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.000669	0.0048	CcSEcCtD
Losartan—SLC22A12—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000662	0.0113	CbGpPWpGaD
Losartan—SLC22A12—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000662	0.0113	CbGpPWpGaD
Losartan—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00066	0.00473	CcSEcCtD
Losartan—SLC2A9—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000645	0.0111	CbGpPWpGaD
Losartan—SLC2A9—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000641	0.011	CbGpPWpGaD
Losartan—SLC2A9—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000641	0.011	CbGpPWpGaD
Losartan—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.000638	0.00457	CcSEcCtD
Losartan—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.000638	0.00457	CcSEcCtD
Losartan—Gout—Hydrochlorothiazide—nephrolithiasis	0.000634	0.00454	CcSEcCtD
Losartan—SLC22A6—cortex of kidney—nephrolithiasis	0.000611	0.00956	CbGeAlD
Losartan—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.000606	0.00435	CcSEcCtD
Losartan—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.000603	0.00432	CcSEcCtD
Losartan—UGT1A1—renal system—nephrolithiasis	0.000601	0.00941	CbGeAlD
Losartan—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.000599	0.0043	CcSEcCtD
Losartan—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000592	0.00424	CcSEcCtD
Losartan—SLC22A12—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00059	0.0101	CbGpPWpGaD
Losartan—SLC22A12—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000586	0.01	CbGpPWpGaD
Losartan—SLC22A12—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000586	0.01	CbGpPWpGaD
Losartan—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.000581	0.00417	CcSEcCtD
Losartan—UGT1A1—kidney—nephrolithiasis	0.000581	0.00909	CbGeAlD
Losartan—AGTR1—nephron tubule—nephrolithiasis	0.000577	0.00903	CbGeAlD
Losartan—SLC2A9—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000571	0.00978	CbGpPWpGaD
Losartan—UGT1A3—Phase II conjugation—SLC26A1—nephrolithiasis	0.000559	0.00957	CbGpPWpGaD
Losartan—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.000559	0.00401	CcSEcCtD
Losartan—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.000556	0.00398	CcSEcCtD
Losartan—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.000535	0.00384	CcSEcCtD
Losartan—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.000527	0.00378	CcSEcCtD
Losartan—AGTR1—renal system—nephrolithiasis	0.000525	0.00821	CbGeAlD
Losartan—SLC22A12—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000522	0.00894	CbGpPWpGaD
Losartan—SLC2A9—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000522	0.00894	CbGpPWpGaD
Losartan—SLC2A9—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000522	0.00894	CbGpPWpGaD
Losartan—AGTR1—kidney—nephrolithiasis	0.000507	0.00794	CbGeAlD
Losartan—SLCO1B1—renal system—nephrolithiasis	0.0005	0.00783	CbGeAlD
Losartan—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.000496	0.00356	CcSEcCtD
Losartan—AGTR1—cortex of kidney—nephrolithiasis	0.000494	0.00773	CbGeAlD
Losartan—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.000494	0.00354	CcSEcCtD
Losartan—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.000489	0.00351	CcSEcCtD
Losartan—Swelling—Hydrochlorothiazide—nephrolithiasis	0.000487	0.00349	CcSEcCtD
Losartan—SLCO1B1—kidney—nephrolithiasis	0.000484	0.00757	CbGeAlD
Losartan—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00048	0.00344	CcSEcCtD
Losartan—SLC22A12—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000478	0.00818	CbGpPWpGaD
Losartan—SLC22A12—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000478	0.00818	CbGpPWpGaD
Losartan—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.000476	0.00341	CcSEcCtD
Losartan—UGT2B7—Phase II conjugation—SLC26A1—nephrolithiasis	0.000475	0.00814	CbGpPWpGaD
Losartan—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.000472	0.00338	CcSEcCtD
Losartan—Injury—Hydrochlorothiazide—nephrolithiasis	0.000467	0.00335	CcSEcCtD
Losartan—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.000463	0.00332	CcSEcCtD
Losartan—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.000455	0.00326	CcSEcCtD
Losartan—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.000453	0.00325	CcSEcCtD
Losartan—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.000451	0.00324	CcSEcCtD
Losartan—Purpura—Hydrochlorothiazide—nephrolithiasis	0.000446	0.0032	CcSEcCtD
Losartan—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.000442	0.00317	CcSEcCtD
Losartan—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.000431	0.00309	CcSEcCtD
Losartan—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00043	0.00308	CcSEcCtD
Losartan—ACE—nephron tubule—nephrolithiasis	0.000426	0.00667	CbGeAlD
Losartan—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.000426	0.00306	CcSEcCtD
Losartan—Migraine—Hydrochlorothiazide—nephrolithiasis	0.000423	0.00303	CcSEcCtD
Losartan—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.000415	0.00297	CcSEcCtD
Losartan—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.000404	0.0029	CcSEcCtD
Losartan—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.000402	0.00289	CcSEcCtD
Losartan—SLC2A9—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000396	0.00678	CbGpPWpGaD
Losartan—SLC2A9—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000396	0.00678	CbGpPWpGaD
Losartan—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.000394	0.00282	CcSEcCtD
Losartan—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.000392	0.00281	CcSEcCtD
Losartan—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.000388	0.00278	CcSEcCtD
Losartan—ACE—renal system—nephrolithiasis	0.000388	0.00606	CbGeAlD
Losartan—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.000387	0.00663	CbGpPWpGaD
Losartan—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.000387	0.00277	CcSEcCtD
Losartan—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.000387	0.00277	CcSEcCtD
Losartan—UGT1A1—Phase II conjugation—SLC26A1—nephrolithiasis	0.000386	0.00661	CbGpPWpGaD
Losartan—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00038	0.00273	CcSEcCtD
Losartan—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.000379	0.00272	CcSEcCtD
Losartan—ACE—kidney—nephrolithiasis	0.000375	0.00586	CbGeAlD
Losartan—UGT1A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.000373	0.00638	CbGpPWpGaD
Losartan—Influenza—Hydrochlorothiazide—nephrolithiasis	0.000371	0.00266	CcSEcCtD
Losartan—SLC2A9—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000368	0.0063	CbGpPWpGaD
Losartan—ACE—cortex of kidney—nephrolithiasis	0.000365	0.00571	CbGeAlD
Losartan—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000364	0.00261	CcSEcCtD
Losartan—SLC22A12—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000362	0.0062	CbGpPWpGaD
Losartan—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.000362	0.00259	CcSEcCtD
Losartan—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00036	0.00616	CbGpPWpGaD
Losartan—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.000345	0.00247	CcSEcCtD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000344	0.00588	CbGpPWpGaD
Losartan—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.000343	0.00246	CcSEcCtD
Losartan—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.000342	0.00245	CcSEcCtD
Losartan—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.000339	0.00243	CcSEcCtD
Losartan—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.000338	0.00242	CcSEcCtD
Losartan—SLC22A12—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000337	0.00576	CbGpPWpGaD
Losartan—SLC22A12—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000337	0.00576	CbGpPWpGaD
Losartan—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.000335	0.0024	CcSEcCtD
Losartan—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.000333	0.00239	CcSEcCtD
Losartan—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.000328	0.00235	CcSEcCtD
Losartan—SLC2A9—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000328	0.00562	CbGpPWpGaD
Losartan—SLC2A9—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000328	0.00562	CbGpPWpGaD
Losartan—UGT1A3—Biological oxidations—SLC26A1—nephrolithiasis	0.000327	0.0056	CbGpPWpGaD
Losartan—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.000325	0.00233	CcSEcCtD
Losartan—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.000325	0.00233	CcSEcCtD
Losartan—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.000323	0.00231	CcSEcCtD
Losartan—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.000322	0.00231	CcSEcCtD
Losartan—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.000322	0.00231	CcSEcCtD
Losartan—Sweating—Hydrochlorothiazide—nephrolithiasis	0.000317	0.00228	CcSEcCtD
Losartan—UGT2B7—NRF2 pathway—SLC2A9—nephrolithiasis	0.000317	0.00543	CbGpPWpGaD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000314	0.00538	CbGpPWpGaD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000314	0.00538	CbGpPWpGaD
Losartan—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.000312	0.00224	CcSEcCtD
Losartan—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.000311	0.00223	CcSEcCtD
Losartan—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.000309	0.00222	CcSEcCtD
Losartan—UGT2B17—Metabolism—GRHPR—nephrolithiasis	0.0003	0.00514	CbGpPWpGaD
Losartan—SLC22A12—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.0003	0.00514	CbGpPWpGaD
Losartan—SLC22A12—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.0003	0.00514	CbGpPWpGaD
Losartan—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.000298	0.00214	CcSEcCtD
Losartan—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.000297	0.00213	CcSEcCtD
Losartan—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.000296	0.00212	CcSEcCtD
Losartan—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.000295	0.00212	CcSEcCtD
Losartan—AGTR1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000294	0.00504	CbGpPWpGaD
Losartan—CYP2C8—renal system—nephrolithiasis	0.000285	0.00445	CbGeAlD
Losartan—CYP3A5—nephron tubule—nephrolithiasis	0.000282	0.00442	CbGeAlD
Losartan—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.000281	0.00201	CcSEcCtD
Losartan—UGT2B7—Biological oxidations—SLC26A1—nephrolithiasis	0.000278	0.00476	CbGpPWpGaD
Losartan—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.000277	0.00199	CcSEcCtD
Losartan—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000276	0.00198	CcSEcCtD
Losartan—CYP2C8—kidney—nephrolithiasis	0.000275	0.0043	CbGeAlD
Losartan—UGT2B17—Metabolism—AGXT—nephrolithiasis	0.000267	0.00458	CbGpPWpGaD
Losartan—CYP1A2—renal system—nephrolithiasis	0.000266	0.00416	CbGeAlD
Losartan—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.000265	0.0019	CcSEcCtD
Losartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000263	0.00451	CbGpPWpGaD
Losartan—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.000263	0.00188	CcSEcCtD
Losartan—SLC2A9—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000262	0.00449	CbGpPWpGaD
Losartan—Erythema—Hydrochlorothiazide—nephrolithiasis	0.000259	0.00186	CcSEcCtD
Losartan—UGT1A1—NRF2 pathway—SLC2A9—nephrolithiasis	0.000258	0.00441	CbGpPWpGaD
Losartan—CYP3A5—renal system—nephrolithiasis	0.000257	0.00402	CbGeAlD
Losartan—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000255	0.00183	CcSEcCtD
Losartan—Tension—Hydrochlorothiazide—nephrolithiasis	0.000254	0.00182	CcSEcCtD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000254	0.00435	CbGpPWpGaD
Losartan—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000253	0.00182	CcSEcCtD
Losartan—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.000251	0.0018	CcSEcCtD
Losartan—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00025	0.00179	CcSEcCtD
Losartan—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.000249	0.00178	CcSEcCtD
Losartan—CYP3A5—kidney—nephrolithiasis	0.000248	0.00388	CbGeAlD
Losartan—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000244	0.00175	CcSEcCtD
Losartan—Tremor—Hydrochlorothiazide—nephrolithiasis	0.000242	0.00174	CcSEcCtD
Losartan—CYP3A5—cortex of kidney—nephrolithiasis	0.000242	0.00378	CbGeAlD
Losartan—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00024	0.00172	CcSEcCtD
Losartan—SLC22A12—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00024	0.00411	CbGpPWpGaD
Losartan—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000239	0.00171	CcSEcCtD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000238	0.00408	CbGpPWpGaD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000238	0.00408	CbGpPWpGaD
Losartan—Agitation—Hydrochlorothiazide—nephrolithiasis	0.000238	0.0017	CcSEcCtD
Losartan—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000236	0.0017	CcSEcCtD
Losartan—Malaise—Hydrochlorothiazide—nephrolithiasis	0.000233	0.00167	CcSEcCtD
Losartan—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.000232	0.00167	CcSEcCtD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000232	0.00397	CbGpPWpGaD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000232	0.00397	CbGpPWpGaD
Losartan—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000232	0.00166	CcSEcCtD
Losartan—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.000232	0.00166	CcSEcCtD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000231	0.00395	CbGpPWpGaD
Losartan—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000229	0.00164	CcSEcCtD
Losartan—UGT2B17—Metabolism—SLC26A1—nephrolithiasis	0.000227	0.00389	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—APRT—nephrolithiasis	0.000227	0.00389	CbGpPWpGaD
Losartan—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000227	0.00163	CcSEcCtD
Losartan—UGT1A1—Biological oxidations—SLC26A1—nephrolithiasis	0.000226	0.00387	CbGpPWpGaD
Losartan—Cough—Hydrochlorothiazide—nephrolithiasis	0.000226	0.00162	CcSEcCtD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000221	0.00379	CbGpPWpGaD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000221	0.00379	CbGpPWpGaD
Losartan—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00022	0.00158	CcSEcCtD
Losartan—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00022	0.00158	CcSEcCtD
Losartan—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00022	0.00158	CcSEcCtD
Losartan—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.000219	0.00157	CcSEcCtD
Losartan—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.000218	0.00156	CcSEcCtD
Losartan—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000215	0.00154	CcSEcCtD
Losartan—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000213	0.00153	CcSEcCtD
Losartan—AGTR1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000213	0.00365	CbGpPWpGaD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000211	0.00362	CbGpPWpGaD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000211	0.00362	CbGpPWpGaD
Losartan—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000211	0.00151	CcSEcCtD
Losartan—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000211	0.00151	CcSEcCtD
Losartan—Shock—Hydrochlorothiazide—nephrolithiasis	0.000208	0.00149	CcSEcCtD
Losartan—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.000207	0.00148	CcSEcCtD
Losartan—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000206	0.00148	CcSEcCtD
Losartan—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.000204	0.00146	CcSEcCtD
Losartan—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000201	0.00144	CcSEcCtD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000197	0.00338	CbGpPWpGaD
Losartan—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.000197	0.00141	CcSEcCtD
Losartan—SLCO1B3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000196	0.00335	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000196	0.00335	CbGpPWpGaD
Losartan—CYP3A4—renal system—nephrolithiasis	0.000193	0.00301	CbGeAlD
Losartan—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000192	0.00138	CcSEcCtD
Losartan—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000191	0.00137	CcSEcCtD
Losartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00019	0.00326	CbGpPWpGaD
Losartan—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00019	0.00136	CcSEcCtD
Losartan—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000188	0.00135	CcSEcCtD
Losartan—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000188	0.00135	CcSEcCtD
Losartan—CYP3A4—kidney—nephrolithiasis	0.000186	0.00291	CbGeAlD
Losartan—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000186	0.00133	CcSEcCtD
Losartan—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000184	0.00132	CcSEcCtD
Losartan—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000182	0.00131	CcSEcCtD
Losartan—Pain—Hydrochlorothiazide—nephrolithiasis	0.000181	0.00129	CcSEcCtD
Losartan—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000181	0.00129	CcSEcCtD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000176	0.00301	CbGpPWpGaD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000176	0.00301	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000175	0.00299	CbGpPWpGaD
Losartan—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000174	0.00125	CcSEcCtD
Losartan—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000173	0.00124	CcSEcCtD
Losartan—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000168	0.0012	CcSEcCtD
Losartan—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.000167	0.0012	CcSEcCtD
Losartan—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000167	0.0012	CcSEcCtD
Losartan—AGTR1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000165	0.00282	CbGpPWpGaD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000164	0.0028	CbGpPWpGaD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000164	0.0028	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—AQP1—nephrolithiasis	0.000162	0.00277	CbGpPWpGaD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00016	0.00274	CbGpPWpGaD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00016	0.00274	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00016	0.00273	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00016	0.00273	CbGpPWpGaD
Losartan—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000156	0.00112	CcSEcCtD
Losartan—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000151	0.00109	CcSEcCtD
Losartan—ABCB1—nephron tubule—nephrolithiasis	0.00015	0.00235	CbGeAlD
Losartan—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000149	0.00107	CcSEcCtD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000149	0.00255	CbGpPWpGaD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000149	0.00255	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—CHRM3—nephrolithiasis	0.000147	0.00251	CbGpPWpGaD
Losartan—SLC22A6—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000146	0.0025	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000145	0.00248	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000145	0.00248	CbGpPWpGaD
Losartan—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000144	0.00104	CcSEcCtD
Losartan—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.000141	0.00242	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000141	0.00241	CbGpPWpGaD
Losartan—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00014	0.001	CcSEcCtD
Losartan—CYP3A5—Biological oxidations—SLC26A1—nephrolithiasis	0.000137	0.00235	CbGpPWpGaD
Losartan—ABCB1—renal system—nephrolithiasis	0.000136	0.00213	CbGeAlD
Losartan—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000134	0.000963	CcSEcCtD
Losartan—Rash—Hydrochlorothiazide—nephrolithiasis	0.000133	0.000955	CcSEcCtD
Losartan—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000133	0.000954	CcSEcCtD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000133	0.00227	CbGpPWpGaD
Losartan—Headache—Hydrochlorothiazide—nephrolithiasis	0.000132	0.000949	CcSEcCtD
Losartan—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000132	0.00226	CbGpPWpGaD
Losartan—ABCB1—kidney—nephrolithiasis	0.000132	0.00206	CbGeAlD
Losartan—SLCO1B1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000132	0.00225	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000132	0.00225	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000129	0.00221	CbGpPWpGaD
Losartan—ABCB1—cortex of kidney—nephrolithiasis	0.000128	0.00201	CbGeAlD
Losartan—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000125	0.000899	CcSEcCtD
Losartan—AGTR1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000124	0.00213	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000121	0.00207	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000121	0.00207	CbGpPWpGaD
Losartan—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000121	0.00207	CbGpPWpGaD
Losartan—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000121	0.00207	CbGpPWpGaD
Losartan—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.000119	0.00204	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000118	0.00202	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000118	0.00202	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000117	0.00201	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—RGS14—nephrolithiasis	0.000113	0.00193	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000113	0.00193	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000113	0.00193	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000107	0.00184	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000107	0.00184	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000107	0.00184	CbGpPWpGaD
Losartan—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.000106	0.00182	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.0001	0.00172	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.0001	0.00172	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—PTH—nephrolithiasis	9.82e-05	0.00168	CbGpPWpGaD
Losartan—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	9.68e-05	0.00166	CbGpPWpGaD
Losartan—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	9.14e-05	0.00157	CbGpPWpGaD
Losartan—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	9.14e-05	0.00157	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	8.94e-05	0.00153	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	8.94e-05	0.00153	CbGpPWpGaD
Losartan—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	8.63e-05	0.00148	CbGpPWpGaD
Losartan—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	8.5e-05	0.00146	CbGpPWpGaD
Losartan—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	8.5e-05	0.00146	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—DGKH—nephrolithiasis	8.39e-05	0.00144	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	8.31e-05	0.00142	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	8.31e-05	0.00142	CbGpPWpGaD
Losartan—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	8.27e-05	0.00142	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	8.13e-05	0.00139	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	8.13e-05	0.00139	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	8.02e-05	0.00137	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—ADCY10—nephrolithiasis	7.84e-05	0.00134	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—DGKH—nephrolithiasis	7.62e-05	0.0013	CbGpPWpGaD
Losartan—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	7.58e-05	0.0013	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	7.56e-05	0.00129	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	7.56e-05	0.00129	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	7.52e-05	0.00129	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	7.52e-05	0.00129	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	7.41e-05	0.00127	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	7.41e-05	0.00127	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—GRHPR—nephrolithiasis	7.38e-05	0.00126	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—GRHPR—nephrolithiasis	6.95e-05	0.00119	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	6.74e-05	0.00115	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	6.74e-05	0.00115	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	6.7e-05	0.00115	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—RGS14—nephrolithiasis	6.66e-05	0.00114	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	6.59e-05	0.00113	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	6.59e-05	0.00113	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—AGXT—nephrolithiasis	6.58e-05	0.00113	CbGpPWpGaD
Losartan—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	6.39e-05	0.00109	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—GRHPR—nephrolithiasis	6.27e-05	0.00107	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—AGXT—nephrolithiasis	6.2e-05	0.00106	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	6.13e-05	0.00105	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	6.13e-05	0.00105	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CHRM3—nephrolithiasis	6.07e-05	0.00104	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—AQP1—nephrolithiasis	5.92e-05	0.00101	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	5.87e-05	0.00101	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—SLC26A1—nephrolithiasis	5.59e-05	0.000958	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—APRT—nephrolithiasis	5.59e-05	0.000958	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—AGXT—nephrolithiasis	5.59e-05	0.000958	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—PTH—nephrolithiasis	5.55e-05	0.00095	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CHRM3—nephrolithiasis	5.51e-05	0.000943	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	5.39e-05	0.000922	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	5.37e-05	0.00092	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	5.37e-05	0.00092	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—APRT—nephrolithiasis	5.27e-05	0.000902	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—SLC26A1—nephrolithiasis	5.27e-05	0.000902	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—GRHPR—nephrolithiasis	5.1e-05	0.000873	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—PTH—nephrolithiasis	5.04e-05	0.000863	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—SLC26A1—nephrolithiasis	4.76e-05	0.000814	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—APRT—nephrolithiasis	4.76e-05	0.000814	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—GRHPR—nephrolithiasis	4.67e-05	0.0008	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	4.65e-05	0.000796	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	4.65e-05	0.000796	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—AGXT—nephrolithiasis	4.54e-05	0.000778	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.5e-05	0.000771	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—DGKH—nephrolithiasis	4.5e-05	0.000771	CbGpPWpGaD
Losartan—ALB—Hemostasis—SLC7A9—nephrolithiasis	4.45e-05	0.000762	CbGpPWpGaD
Losartan—ALB—Hemostasis—DGKH—nephrolithiasis	4.45e-05	0.000762	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	4.32e-05	0.00074	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	4.32e-05	0.00074	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—AGXT—nephrolithiasis	4.16e-05	0.000713	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	4.07e-05	0.000697	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	4.07e-05	0.000697	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—AQP1—nephrolithiasis	3.98e-05	0.000682	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—APRT—nephrolithiasis	3.86e-05	0.000662	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—SLC26A1—nephrolithiasis	3.86e-05	0.000662	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	3.85e-05	0.000659	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	3.85e-05	0.000659	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	3.78e-05	0.000648	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	3.78e-05	0.000648	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—AQP1—nephrolithiasis	3.76e-05	0.000643	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—CHRM3—nephrolithiasis	3.6e-05	0.000617	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—APRT—nephrolithiasis	3.54e-05	0.000606	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—SLC26A1—nephrolithiasis	3.54e-05	0.000606	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—CHRM3—nephrolithiasis	3.4e-05	0.000582	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—AQP1—nephrolithiasis	3.39e-05	0.00058	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	3.37e-05	0.000578	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	3.37e-05	0.000578	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CHRM3—nephrolithiasis	3.25e-05	0.000557	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—GRHPR—nephrolithiasis	3.1e-05	0.000531	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	3.08e-05	0.000527	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—CHRM3—nephrolithiasis	3.06e-05	0.000525	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—PTH—nephrolithiasis	2.98e-05	0.00051	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—AGXT—nephrolithiasis	2.76e-05	0.000473	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—AQP1—nephrolithiasis	2.75e-05	0.000471	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	2.7e-05	0.000462	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—GRHPR—nephrolithiasis	2.68e-05	0.00046	CbGpPWpGaD
Losartan—ALB—Metabolism—GRHPR—nephrolithiasis	2.67e-05	0.000457	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—AQP1—nephrolithiasis	2.52e-05	0.000432	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—CHRM3—nephrolithiasis	2.49e-05	0.000426	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—GRHPR—nephrolithiasis	2.4e-05	0.00041	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—AGXT—nephrolithiasis	2.39e-05	0.00041	CbGpPWpGaD
Losartan—ALB—Metabolism—AGXT—nephrolithiasis	2.38e-05	0.000407	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	2.35e-05	0.000402	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—APRT—nephrolithiasis	2.35e-05	0.000402	CbGpPWpGaD
Losartan—ABCB1—Metabolism—GRHPR—nephrolithiasis	2.34e-05	0.000401	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—CHRM3—nephrolithiasis	2.28e-05	0.000391	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—GRHPR—nephrolithiasis	2.19e-05	0.000374	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—AGXT—nephrolithiasis	2.14e-05	0.000366	CbGpPWpGaD
Losartan—ABCB1—Metabolism—AGXT—nephrolithiasis	2.08e-05	0.000357	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—APRT—nephrolithiasis	2.03e-05	0.000348	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	2.03e-05	0.000348	CbGpPWpGaD
Losartan—ALB—Metabolism—APRT—nephrolithiasis	2.02e-05	0.000346	CbGpPWpGaD
Losartan—ALB—Metabolism—SLC26A1—nephrolithiasis	2.02e-05	0.000346	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—AGXT—nephrolithiasis	1.95e-05	0.000334	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—GRHPR—nephrolithiasis	1.87e-05	0.00032	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—APRT—nephrolithiasis	1.82e-05	0.000311	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	1.82e-05	0.000311	CbGpPWpGaD
Losartan—ABCB1—Metabolism—APRT—nephrolithiasis	1.77e-05	0.000304	CbGpPWpGaD
Losartan—ABCB1—Metabolism—SLC26A1—nephrolithiasis	1.77e-05	0.000304	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—AQP1—nephrolithiasis	1.67e-05	0.000287	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—AGXT—nephrolithiasis	1.66e-05	0.000285	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—APRT—nephrolithiasis	1.66e-05	0.000284	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	1.66e-05	0.000284	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—CHRM3—nephrolithiasis	1.51e-05	0.000259	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—SPP1—nephrolithiasis	1.49e-05	0.000256	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—AQP1—nephrolithiasis	1.45e-05	0.000248	CbGpPWpGaD
Losartan—ALB—Metabolism—AQP1—nephrolithiasis	1.44e-05	0.000247	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—GRHPR—nephrolithiasis	1.44e-05	0.000247	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	1.42e-05	0.000242	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—APRT—nephrolithiasis	1.42e-05	0.000242	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—CHRM3—nephrolithiasis	1.31e-05	0.000225	CbGpPWpGaD
Losartan—ALB—Metabolism—CHRM3—nephrolithiasis	1.3e-05	0.000223	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—AQP1—nephrolithiasis	1.29e-05	0.000222	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—AGXT—nephrolithiasis	1.28e-05	0.00022	CbGpPWpGaD
Losartan—ABCB1—Metabolism—AQP1—nephrolithiasis	1.26e-05	0.000216	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—AQP1—nephrolithiasis	1.18e-05	0.000202	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—CHRM3—nephrolithiasis	1.17e-05	0.0002	CbGpPWpGaD
Losartan—ABCB1—Metabolism—CHRM3—nephrolithiasis	1.14e-05	0.000196	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—APRT—nephrolithiasis	1.09e-05	0.000187	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	1.09e-05	0.000187	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—CHRM3—nephrolithiasis	1.07e-05	0.000183	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—AQP1—nephrolithiasis	1.01e-05	0.000173	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—CHRM3—nephrolithiasis	9.12e-06	0.000156	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—AQP1—nephrolithiasis	7.78e-06	0.000133	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—CHRM3—nephrolithiasis	7.04e-06	0.000121	CbGpPWpGaD
